open access

Vol 4, No 3 (2015)
Original articles (submitted)
Published online: 2015-07-16
Get Citation

Lipohypertrophy — undervalued (important) cutaneous complication of insulin therapy in diabetic patients

Michał Długaszek, Anna Krywult, Alicja Daszyk, Katarzyna Dziadzio, Aleksandra Gacek, Katarzyna Zygmund, Adam Gąsior, Krzysztof Strojek
DOI: 10.5603/DK.2015.0009
·
Diabetologia Kliniczna 2015;4(3):104-109.

open access

Vol 4, No 3 (2015)
Original articles (submitted)
Published online: 2015-07-16

Abstract

Introduction. The control of diabetes mellitus (DM) has been improved since the insulin pens were introduced into the diabetes treatment. In pen insulin injection site the new cutaneous complication — lipohypertrophy (LHT) was observed.

Objectives. The assessment of the occurrences and risk factors of LHT in insulin receive patients. Patients and methods. 130 patients of the Regional Outpatient Diabetes Clinic in Zabrze were included to the study. The demographic, clinical characteristic, insulin therapy technique and knowledge about LHT were noticed in. The inclusion criteria: type 1 and 2 DM, > 2 years insulin therapy, insulin pen usage. LHT was defined as subcutaneous lump in ≥ 1 place in physical examination. Patients were divided into 2 groups according to diameter and thickness of LHT.

Results. LHT was observed in 78 (60%) of patients, but 48 (61.5%) patients developed LHT in 1 site, 30 (38.5%) patients developed LHT in > 1 site. 78 (60%) patients could defined LHT, but only 47 (60%) in LHT group. Patients with LHT longer suffer from DM, longer receive insulin and longer use the same needle. They had higher fasting and postprandial glycaemia, higher insulin requirement and more often complain about hypoglycemia. In the multivariate analysis the independent factors for presence of LHT were: needle reuse > 1 day, not changing sites of injection and human insulin usage.

Conclusions. LHT is a common cutaneous complication of insulin pen usage. Risk factors obtained in this study are modifiable and they should be taken into account in daily clinical practice.

Abstract

Introduction. The control of diabetes mellitus (DM) has been improved since the insulin pens were introduced into the diabetes treatment. In pen insulin injection site the new cutaneous complication — lipohypertrophy (LHT) was observed.

Objectives. The assessment of the occurrences and risk factors of LHT in insulin receive patients. Patients and methods. 130 patients of the Regional Outpatient Diabetes Clinic in Zabrze were included to the study. The demographic, clinical characteristic, insulin therapy technique and knowledge about LHT were noticed in. The inclusion criteria: type 1 and 2 DM, > 2 years insulin therapy, insulin pen usage. LHT was defined as subcutaneous lump in ≥ 1 place in physical examination. Patients were divided into 2 groups according to diameter and thickness of LHT.

Results. LHT was observed in 78 (60%) of patients, but 48 (61.5%) patients developed LHT in 1 site, 30 (38.5%) patients developed LHT in > 1 site. 78 (60%) patients could defined LHT, but only 47 (60%) in LHT group. Patients with LHT longer suffer from DM, longer receive insulin and longer use the same needle. They had higher fasting and postprandial glycaemia, higher insulin requirement and more often complain about hypoglycemia. In the multivariate analysis the independent factors for presence of LHT were: needle reuse > 1 day, not changing sites of injection and human insulin usage.

Conclusions. LHT is a common cutaneous complication of insulin pen usage. Risk factors obtained in this study are modifiable and they should be taken into account in daily clinical practice.

Get Citation

Keywords

diabetes mellitus, insulin therapy, lipohypertrophy

About this article
Title

Lipohypertrophy — undervalued (important) cutaneous complication of insulin therapy in diabetic patients

Journal

Clinical Diabetology

Issue

Vol 4, No 3 (2015)

Pages

104-109

Published online

2015-07-16

DOI

10.5603/DK.2015.0009

Bibliographic record

Diabetologia Kliniczna 2015;4(3):104-109.

Keywords

diabetes mellitus
insulin therapy
lipohypertrophy

Authors

Michał Długaszek
Anna Krywult
Alicja Daszyk
Katarzyna Dziadzio
Aleksandra Gacek
Katarzyna Zygmund
Adam Gąsior
Krzysztof Strojek

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl